ExonHit Therapeutics Inc. Signs an Exclusive Agreement with Genmab A/S for Novel Splice Variant Targets in Breast Cancer

ExonHit Therapeutics (Paris:ALEHT) today announced the signing of an exclusive agreement with Genmab A/S for a selection of novel splice variants, identified as part of a successful pilot study, that have the potential to be therapeutic targets for breast cancer. Genmab retains exclusive development and commercialization rights on 10 events out of a breast cancer database developed using ExonHit’s genome-wide SpliceArray™ technology (RNA splicing analysis platform covering the entire genome).